EXEL Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.68 |
| 52 Week High | US$40.02 |
| 52 Week Low | US$20.14 |
| Beta | 0.57 |
| 1 Month Change | -4.20% |
| 3 Month Change | 7.98% |
| 1 Year Change | 56.15% |
| 3 Year Change | 59.97% |
| 5 Year Change | 103.55% |
| Change since IPO | 141.51% |
Recent News & Updates
Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Mar 13Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
Feb 21
Recent updates
Exelixis: Pinning Hopes On Cracking One Of The Toughest Nuts
Mar 13Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
Feb 21Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Jan 09Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Oct 31Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story
Oct 31Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching
Oct 26Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult
Sep 02
Cabozantinib's Momentum And Tactical Growth Amid Market Challenges Propel Biotech Innovation
Aug 27 Strong commercial performance of the cabozantinib franchise, indicating sustained revenue growth through market penetration and diversification into new indications.Exelixis Comes Up Aces
Aug 08If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity
Jun 14It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year
May 24Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality
May 07Exelixis: With Patent Litigation Decision Due Soon, There Are Options
May 02Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors
Apr 22Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
Mar 28Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles
Jan 17Shareholder Returns
| EXEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | -6.2% | -5.6% |
| 1Y | 56.2% | -10.4% | 3.3% |
Return vs Industry: EXEL exceeded the US Biotechs industry which returned -10.4% over the past year.
Return vs Market: EXEL exceeded the US Market which returned 3.3% over the past year.
Price Volatility
| EXEL volatility | |
|---|---|
| EXEL Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.4% |
Stable Share Price: EXEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXEL's weekly volatility (5%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Zanzalintinib Pivotal Trials Will Unveil New Cancer Treatment Options
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,147 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| EXEL fundamental statistics | |
|---|---|
| Market cap | US$10.37b |
| Earnings (TTM) | US$521.27m |
| Revenue (TTM) | US$2.17b |
19.7x
P/E Ratio4.7x
P/S RatioIs EXEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXEL income statement (TTM) | |
|---|---|
| Revenue | US$2.17b |
| Cost of Revenue | US$76.22m |
| Gross Profit | US$2.09b |
| Other Expenses | US$1.57b |
| Earnings | US$521.27m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.86 |
| Gross Margin | 96.49% |
| Net Profit Margin | 24.04% |
| Debt/Equity Ratio | 0% |
How did EXEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/03 05:43 |
| End of Day Share Price | 2025/04/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exelixis, Inc. is covered by 39 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Peter Lawson | Barclays |
| Jason Matthew Gerberry | BofA Global Research |